Key Points
- Director Ghiath Sukhtian bought 2.53 million shares of Oncobiologics at $0.99 each, spending nearly $2.5 million and increasing his ownership by 11.43% to 24.62 million shares.
- Oncobiologics reported a quarterly loss of $0.09 per share, slightly worse than analyst expectations, while revenue of roughly $10,000 fell far short of the $970,000 consensus estimate.
- The company priced a $55 million stock-and-warrant offering, potentially creating significant shareholder dilution; shares opened at $0.76, compared with a consensus analyst price target of $4.65.
Oncobiologics, Inc. (NASDAQ:OTLK - Get Free Report) Director Ghiath Sukhtian acquired 2,525,252 shares of the firm's stock in a transaction that occurred on Wednesday, August 12th. The stock was bought at an average price of $0.99 per share, for a total transaction of $2,499,999.48. Following the completion of the transaction, the director owned 24,617,320 shares of the company's stock, valued at $24,371,146.80. The trade was a 11.43% increase in their position. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this link.
Oncobiologics Price Performance
Shares of OTLK opened at $0.76 on Friday. Oncobiologics, Inc. has a 1-year low of $0.16 and a 1-year high of $3.39. The company has a market capitalization of $112.39 million, a P/E ratio of -0.65 and a beta of 0.82. The firm's 50 day simple moving average is $1.31 and its 200 day simple moving average is $0.70.
Oncobiologics (NASDAQ:OTLK - Get Free Report) last released its quarterly earnings results on Thursday, August 13th. The company reported ($0.09) EPS for the quarter, missing analysts' consensus estimates of ($0.08) by ($0.01). The business had revenue of $0.01 million for the quarter, compared to analyst estimates of $0.97 million. On average, equities analysts anticipate that Oncobiologics, Inc. will post -0.49 earnings per share for the current year.
Oncobiologics News Roundup
Here are the key news stories impacting Oncobiologics this week:
- Positive Sentiment: BTIG Research reaffirmed its “buy” rating and set a $4.00 price target, implying significant potential upside from recent trading levels. Benzinga analyst rating report
- Positive Sentiment: Management highlighted FDA approval of LYTENAVA, an ophthalmic bevacizumab product intended to address the U.S. wet age-related macular degeneration market. The approval could support future commercialization and revenue growth. Outlook Therapeutics third-quarter results and business update
- Positive Sentiment: Director Ghiath M. Sukhtian purchased 2.53 million shares for approximately $2.5 million, increasing his direct ownership by 11.43%. The insider purchase may be viewed as a vote of confidence in the company’s prospects. SEC insider transaction filing
- Neutral Sentiment: The company’s quarterly loss was $0.09 per share, compared with a $0.44 loss a year earlier, indicating year-over-year improvement but still missing the $0.08 consensus estimate. Zacks quarterly earnings report
- Negative Sentiment: Revenue was only approximately $10,000, far below the $970,000 consensus estimate. The revenue shortfall reinforces concerns about the timing of LYTENAVA’s commercial ramp and near-term cash generation. MarketBeat earnings report
- Negative Sentiment: Oncobiologics priced a $55 million public offering of 55.56 million shares at $0.99 each, along with immediately exercisable warrants carrying a $1.10 strike price. The large offering creates substantial dilution and likely contributed to selling pressure. Public offering announcement
Institutional Inflows and Outflows
Large investors have recently made changes to their positions in the business. Russell Investments Group Ltd. lifted its holdings in shares of Oncobiologics by 865.2% in the 2nd quarter. Russell Investments Group Ltd. now owns 24,477 shares of the company's stock worth $39,000 after acquiring an additional 21,941 shares during the last quarter. AQR Capital Management LLC grew its holdings in shares of Oncobiologics by 42.7% during the 1st quarter. AQR Capital Management LLC now owns 84,671 shares of the company's stock valued at $103,000 after purchasing an additional 25,351 shares during the last quarter. Finally, Goldman Sachs Group Inc. grew its holdings in shares of Oncobiologics by 74.1% during the 1st quarter. Goldman Sachs Group Inc. now owns 103,524 shares of the company's stock valued at $126,000 after purchasing an additional 44,063 shares during the last quarter. 11.20% of the stock is owned by hedge funds and other institutional investors.
Wall Street Analysts Forecast Growth
OTLK has been the subject of several research reports. Weiss Ratings upgraded shares of Oncobiologics from a "sell (e+)" rating to a "sell (d-)" rating in a research report on Wednesday. BTIG Research reissued a "buy" rating and issued a $4.00 target price on shares of Oncobiologics in a research note on Friday. HC Wainwright raised their price target on Oncobiologics to $1.60 and gave the company a "neutral" rating in a research report on Monday, July 27th. Wall Street Zen lowered Oncobiologics from a "hold" rating to a "sell" rating in a research note on Saturday. Finally, Ascendiant Capital Markets upped their price objective on Oncobiologics from $6.00 to $10.00 and gave the stock a "buy" rating in a report on Thursday, June 11th. Two investment analysts have rated the stock with a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Oncobiologics currently has an average rating of "Hold" and a consensus price target of $4.65.
Get Our Latest Report on Oncobiologics
Oncobiologics Company Profile
(
Get Free Report)
Oncobiologics, Inc is a clinical-stage biopharmaceutical company specializing in the development of biosimilar therapeutics for cancer and autoimmune diseases. Leveraging recombinant DNA technology and advanced formulation platforms, the company aims to create high-quality, cost-effective alternatives to originator biologic drugs. Oncobiologics' research focus includes monoclonal antibodies and growth factors that support oncology treatment and immunomodulation.
Founded in 2005 and headquartered in Marlborough, Massachusetts, Oncobiologics maintains research facilities in the Greater Boston area and an integrated manufacturing site in Hyderabad, India, through its wholly owned subsidiary.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
